Skip to main content

Elsbernd Brian's Form 4 filing

Catalyst Pharmaceuticals, Inc. (CPRX) · filed Nov 29, 2024

Accession no.
0001161697-24-000490
Filed
Nov 29, 2024
Trade date
Nov 26, 2024
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $286.7K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Elsbernd BrianCIK 0001763511Officer (Chief Compliance/Legal Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 26, 2024Common Stock, par value $0.001 per shareMOption exerciseAcquired+50,244$4.01+$201,478.44174,677Direct
Nov 26, 2024Common Stock, par value $0.001 per shareSSaleDisposed−9,300$21.65−$201,345165,377Direct
Nov 26, 2024Common Stock, par value $0.001 per shareMOption exerciseAcquired+9,756$4.01+$39,121.56175,133Direct
Nov 26, 2024Common Stock, par value $0.001 per shareSSaleDisposed−3,956$21.58−$85,370.48171,177Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 26, 2024Common StockMOption exerciseDisposed−50,244$0.00$01,104,766Direct
Nov 26, 2024Common StockMOption exerciseDisposed−9,756$0.00$01,095,010Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)